Skip to main content

Sarcoma of unknown primary: myth or reality?



Sarcoma of unknown primary (SUP) designates an enigmatic entity with histologic confirmation of a metastatic tumor without an identifiable primary after a thorough diagnostic workup. The term “unknown primary” is heavily debatable given that sarcomas can arise from any tissue that harbors its histological structure. In this review, we discuss the validity of SUP as a distinct entity.

Main body of the abstract

Medline/PubMed and Google Scholar were searched from 1990 until April 2020 for publications in the English language reporting on SUP. We excluded articles reporting on cases with sarcomas from known organ sites such as lung or uterine sarcomas as well as synovial sarcomas. The Kaplan–Meier method was used to compute the median overall survival. A total of 26 patients with SUP were identified. The median age at diagnosis was 17.5 years with a similar prevalence among men and women. The tumors most commonly reported were alveolar rhabdomyosarcoma and rhabdomyosarcoma not otherwise specified. Almost two-thirds of the patients were reported to have more than one metastatic site. Among the 13 patients with survival data, the median overall survival was 10.0 months. Two patients underwent autopsy and had their primary culprit identified in the chest wall and paravertebral.


This review showed that SUP shares with sarcomas of known primary similar clinical features including an aggressive clinical course, generally poor response to chemotherapy, and dismal patient outcomes. Thus, SUP does not appear to display a different natural history and biological properties that would allude to a distinct entity.


Sarcomas enclose a group of heterogeneous malignancies that constitute approximately 1% of human malignancies [1]. These tumors are traditionally categorized according to their clinical presentation into low-grade tumors with minimal metastatic potential and highly aggressive cancers with a tendency for systemic metastasis [2]. The molecular advances over the last two decades identified two groups of sarcomas. The first group is characterized by a tumor-specific translocation that is central to sarcomagenesis and the second presents genetic instability that manifests in a complex karyotype [3]. Both subsets can arise for the mesenchymal tissue in almost every organ and can lead to soft tissue tumors at any site without being attributed to any organ [4, 5]. Although sarcomas arise in tissues of mesenchymal lineages including bone, muscle and cartilage, several publications have reported on the occurrence of sarcomas in the absence of an identifiable primary (supplementary material). Historically, sarcomas of unknown primaries (SUP) accounted for approximately 3.2% of cancers of unknown primary although the term “unknown primary” is heavily debatable among sarcoma experts given that sarcomas of different types can arise from any organ or tissue that harbors its histological structure [6]. For instance, the term synovial sarcoma seems to be carried over from older literature that diagnosed synovial differentiation based on the propensity for this malignancy to originate in periarticular regions and the presence (especially in biphasic cases) of some reminiscent histology [7]. The traditionally reported synovial sarcomas of unknown primary are in fact synovial sarcomas of unusual sites. Therefore, we performed a systematic review and individual-based meta-analysis to assess and discuss whether SUP may be considered as a valid distinct entity.

Main text


Medline/PubMed and Google Scholar were searched from 1990 until April 2020 for publications in the English language reporting on SUP. The search was carried out using mainly (“Sarcoma”[Mesh]) AND “Neoplasms, Unknown Primary”[Mesh]) in Medline or the following keywords such as “Sarcoma”, “Soft-tissue sarcoma”, “Cancer of Unknown Primary” in Google Scholar. Two medical oncologists (ER and NP) reviewed the publication titles and abstracts for relevance and then assessed the references of these papers to ensure the exhaustiveness of the selection process. A pathologist (RAJ) also reviewed the selected cases to confirm eligibility. We excluded articles reporting on cases with synovial sarcomas occurring in unusual sites according to the world health classification of soft tissue tumors published in 2020 [8]. These sites included external and internal reproductive organs, kidney, adrenal gland, retroperitoneum, stomach, small bowel, lung, heart, mediastinum, bone, central nervous system, and peripheral nerve. The individual-patient data reported were extracted from the selected papers and entered into an excel sheet for analyses (supplementary material). Descriptive statistics were used to report on the patient and tumor characteristics, including age, gender, metastatic sites, and diagnostic workup. The Kaplan–Meier method estimated the overall survival defined from the date of diagnosis to the date of death from all causes; the patients who were alive at the time of publication were censored. We did not perform univariable or multivariable analysis given the small number of patients with survival outcomes (n = 13). All statistical analyses were performed using IBM© SPSS© Statistics version 26.


Overall, 26 patients fulfilled the eligibility criteria for this study and were eligible for analysis. The median age at diagnosis was of 17.5 years (range 3–83 years) with a similar prevalence among men and women. The commonly reported pathologies were alveolar rhabdomyosarcoma (n = 7; 26.9%), rhabdomyosarcoma not otherwise specified (n = 7; 26.9%), and sarcoma not otherwise specified (n = 3; 11.5%). Almost two-thirds of the patients had 2 or more metastatic sites including mainly the brain, bone (including bone marrow), lung, and lymph nodes in 16.7%, 68.8%, 52.9%, and 29.4%, respectively (Table 1). All patients underwent standard morphology and immunohistochemistry studies whereas only four cases had molecular pathology investigations. Among the 11 cases reporting on the diagnostic workup, MRI was used in 18.2%, bone scan in 45.5%, and PET-CT scan in 27.3%. Systemic chemotherapy was administered in 88.2% of patients with only two cases receiving more than one line of chemotherapy. The chemotherapy regimens used were mainly sarcoma-type chemotherapies such as vincristine, topotecan plus cyclophosphamide, doxorubicin plus cyclophosphamide, or vincristine, doxorubicin plus cyclophosphamide. The survival analysis of the 13 patients with available survival data showed a median overall survival of 10.0 months (95% CI 2.9–17.0 months) and 1-year overall survival of 50% (Fig. 1). Two patients underwent autopsy and had their primary culprit identified in the chest wall and paravertebral space.

Table 1 Summary of the patients characteristics, diagnostic workup, and treatment modalities
Fig. 1
figure 1

The survival analysis of the 13 patients with available survival data


The historical definition of cancers of unknown primary was based on clinical findings of a multiple tumors site without an identifiable primary and did not require histologic confirmation of the malignancy. This approach was quickly abandoned to the current strategies which mandate pathologic confirmation of the malignancy to guide treatment decisions [9, 10]. The occurrence of SUP is not theoretically valid because sarcomas can arise from any primitive mesenchymal cells and thus in any organ. However, given the complexity and heterogeneity of sarcomas misdiagnosis and incomplete diagnostic workups are not uncommon. From our experience with patients diagnosed with cancers of unknown primary and sarcomas consulting for second opinion at our centers, the diagnostic workups differ widely among centers and patients. For instance, the European Society of Medical Oncology (ESMO) guidelines for sarcoma recommend a centralized pathology review because major discordances occur in 8 to 11% and minor discordances in 16 to 35% [11, 12]. The pathologies of the patients diagnosed with SUP were highly variable reflecting a histologic heterogeneity that complicates diagnostic confirmations (Table 1). In a case series of 96 nonrandomly selected cases with CUP, the accuracy of cytology and transmission electron microscopy in diagnosing tumor category using biopsy results as the gold standard was 78% and 91%, respectively [13]. Among the three cases with sarcoma (2 patients with leiomyosarcoma and 1 with malignant fibrous histiocytoma), the accuracy for diagnosing tumor type was 67% by cytology and 100% by transmission electron microscopy [13]. Moreover, the ESMO guidelines favor molecular diagnostic studies among cases with unusual clinical pathological presentations, thus their indication among patients misdiagnosed with SUP [14]. Only a minority of the patients diagnosed with SUP had molecular pathology investigations although molecular studies were diagnostic in many patients with synovial sarcoma that would be initially considered SUP [15, 16].

The mandatory diagnostic standard for cancers of unknown primary laid down by the European Society of Medical Oncology guidelines includes a CT scan of the chest, abdomen, and pelvis that seemed to be left out in many patients (Table 1). The delicate aspect of this topic is to judge whether a tumor site should be considered the primary culprit or metastatic dissemination to guide treatment decisions. The possible theoretical explanation model for the SUP phenomenon is the smallness of the primary tumor that evades detection or inadequate workup. For example, two patients included in this study underwent autopsy and had their primary culprit identified in the chest wall and paravertebral space. As almost two-thirds of the patients had more than one metastatic site, systemic chemotherapy was the main treatment strategy. Nevertheless, chemotherapy was commonly limited to one line of treatment and the overall survival was dismal. The METASARC observation study reported similar outcomes among 2225 patients with metastatic soft-tissue sarcomas treated in the real-life setting [17]. The median number of systemic treatments was 3 (range, 1–6) with 27% of the patients not receiving any systemic treatment [17]. Almost half the patients underwent locoregional treatment of the metastasis. The median overall survival ranged between 5.4 and 8.5 months and correlated to gender, leiomyosarcoma histologies, locoregional treatment of metastases, and treated with polychemotherapy [17]. Unfortunately, the sample size of patients with SUP reported in the literature was small which limited correlation studies.


This review showed that SUP shares with sarcomas of known primary similar clinical features, including aggressive clinical course, generally poor response to chemotherapy, and dismal patient outcomes. Thus, SUP does not appear to display a different natural history and biological properties that would allude to a distinct entity. However, this study includes several limitations that are inherent to the study design. The major difficulty encountered in reviewing the literature involved the modifications in the diagnostic criteria of sarcomas. Morphology and immunohistochemistry analysis have been occasionally a topic of disagreement among pathologists which required ancillary molecular diagnostics. Unfortunately, the published literature, mainly the older publications, lack molecular pathology investigations whereas the general approach consists of classifying sarcomas according to their genomic characteristics as either sarcoma with a complex genomic profile or sarcoma with a single underlying (or driver) genetic or molecular-biological abnormality (including translocation, gain-of-function mutation, amplification, or tumor suppressor gene loss) [18,19,20,21]. We believe that the small sample and heterogeneity of the study limited our analysis. Large well-validated population-based registries, such as the Surveillance, Epidemiology, and End Results (SEER) program, and more importantly large sarcoma network-based registries should be investigated to confirm whether SUP remains a myth.

Availability of data and materials

The datasets used and/or analyzed during the current study are available in the supplementary material.



Sarcoma of unknown primary


Computed tomography


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    PubMed  Google Scholar 

  2. Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, et al. The epigenomics of sarcoma. Nat Rev Cancer. 2020;20(10):608–23.

    Article  CAS  Google Scholar 

  3. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003;3(9):685–94.

    Article  CAS  Google Scholar 

  4. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428–35.

    Article  Google Scholar 

  5. Rassy E, Pavlidis N. The diagnostic challenges of patients with carcinoma of unknown primary. Expert Rev Anticancer Ther. 2020;20(9):775–83.

    Article  CAS  Google Scholar 

  6. Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg. 2007;194(6):833–7 discussion 837-838.

    Article  Google Scholar 

  7. Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 2015;5(2):124–34.

    Article  CAS  Google Scholar 

  8. Choi JH, Ro JY. The 2020 WHO classification of tumors of soft tissue: selected changes and new entities. Adv Anat Pathol. 2021;28(1):44–58.

    Article  Google Scholar 

  9. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer. 1986;57(1):120–4.

    Article  CAS  Google Scholar 

  10. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer. 2002;38(13):1810–2.

    Article  CAS  Google Scholar 

  11. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2015;26:v133–8.

    Article  Google Scholar 

  12. Ray-Coquard I, Montesco MC, Coindre JM, Dei Tos AP, Lurkin A, Ranchère-Vince D, et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol sept. 2012;23(9):2442–9.

    Article  CAS  Google Scholar 

  13. Facundo DJ, Quinonez G, Ravinsky E. Transmission electron microscopy of fine needle aspiration biopsies of metastases. Accuracy of both techniques as established by biopsy diagnoses. Acta Cytol. 2003;47(3):457–62.

    Article  Google Scholar 

  14. Gronchi A, Miah AB, Tos APD, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–65.

    Article  CAS  Google Scholar 

  15. DeBoard ZM, West PN. Pulmonary synovial sarcoma of unknown origin. Am Surg. 2016;82(2):E40–2.

    Article  Google Scholar 

  16. Zhang G, Xiao B, Huang H, Zhang Y, Zhang X, Zhang J, et al. Intracranial synovial sarcoma: a clinical, radiological and pathological study of 16 cases. Eur J Surg Oncol déc. 2019;45(12):2379–85.

    Article  Google Scholar 

  17. Savina M, Le Cesne A, Blay J-Y, Ray-Coquard I, Mir O, Toulmonde M, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15(1):78.

    Article  Google Scholar 

  18. Dufresne A, Brahmi M, Karanian M, Blay J-Y. Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. Nat Rev Clin Oncol. 2018;15(7):443–58.

    Article  Google Scholar 

  19. Assi T, Rassy E, Nassereddine H, Farhat F, Kattan J. Epithelioid sarcoma as the prototype for personalized therapy in soft tissue sarcoma. Per Med. 2020;17(4):241-4.

  20. Assi T, Kattan J, El Rassy E, Honore C, Dumont S, Mir O, et al. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. Cancer Treat Rev. 2019;72:37–44.

    Article  CAS  Google Scholar 

  21. Assi T, Kattan J, Rassy E, Nassereddine H, Farhat F, Honore C, Le Cesne A, Adam J, Mir O. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. Crit Rev Oncol Hematol. 2020;153:103029.

Download references




No funding.

Author information

Authors and Affiliations



ER and NP: concept and drafting; RAJ: pathology review; all authors contributed to the revision and drafting of the manuscript; and all authors approved the final version.

Corresponding author

Correspondence to Elie Rassy.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Professor Hussein Khaled is a co-author of this study and Editor-in-Chief for the journal. He declares a competing interest for this submission. He was not involved in handling this manuscript during the submission and review processes. The rest of the authors have no conflict of interest to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplementary Table 1.

Studies included in this analysis.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rassy, E., Abou-Jaoude, R., Boussios, S. et al. Sarcoma of unknown primary: myth or reality?. J Egypt Natl Canc Inst 34, 27 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Cancer of unknown primary
  • Sarcoma
  • Soft-tissue sarcoma of unknown primary